Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
153 hedge funds and large institutions have $2.22B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 63 increasing their positions, 35 reducing their positions, and 13 closing their positions.
254% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 13
85% more capital invested
Capital invested by funds: $1.2B → $2.22B (+$1.02B)
80% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 35
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
25% more funds holding
Funds holding: 122 → 153 (+31)
25% more call options, than puts
Call options by funds: $62.3M | Put options by funds: $49.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$74.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$57.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$36M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$23.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$126M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
-$47M |
| 3 |
O
OrbiMed
New York
|
-$45M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$24.1M |
| 5 |
Alkeon Capital Management
New York
|
-$20.5M |
DCPH Hedge Fund Activity: Q4 2019 in Review
153 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2019, worth a combined $2.22B — up 85% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new DCPH positions and 13 closed out — a net gain of 33 holders — while 63 added to existing stakes and 35 trimmed.
The largest buyer was Franklin Resources, adding an estimated $74.3M. The largest seller was Millennium Management, cutting an estimated $126M.
- 153 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2019, up from 122 in Q3 2019.
- Funds reported $2.22B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2019, up 85% quarter-over-quarter.
- 46 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 13 closed out, a net change of +33 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was Franklin Resources, an estimated $74.3M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Millennium Management, an estimated $126M sold.
Based on aggregated 13F filings for Q4 2019.